Understanding the pathogenic mechanisms and therapeutic effects in neurocysticercosis.
Peru
anthelmintics
axonal swelling
neurocysticercosis
neuropathology
spheroids
Journal
Brain pathology (Zurich, Switzerland)
ISSN: 1750-3639
Titre abrégé: Brain Pathol
Pays: Switzerland
ID NLM: 9216781
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
received:
25
09
2023
accepted:
01
01
2024
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
Despite being a leading cause of acquired seizures in endemic regions, the pathological mechanisms of neurocysticercosis are still poorly understood. This study aims to investigate the impact of anthelmintic treatment on neuropathological features in a rat model of neurocysticercosis. Rats were intracranially infected with Taenia solium oncospheres and treated with albendazole + praziquantel (ABZ), oxfendazole + praziquantel (OXF), or untreated placebo (UT) for 7 days. Following the last dose of treatment, brain tissues were evaluated at 24 h and 2 months. We performed neuropathological assessment for cyst damage, perilesional brain inflammation, presence of axonal spheroids, and spongy changes. Both treatments showed comparable efficacy in cyst damage and inflammation. The presence of spongy change correlated with spheroids counts and were not affected by anthelmintic treatment. Compared to white matter, gray matter showed greater spongy change (91.7% vs. 21.4%, p < 0.0001), higher spheroids count (45.2 vs. 0.2, p = 0.0001), and increased inflammation (72.0% vs. 21.4%, p = 0.003). In this rat model, anthelmintic treatment destroyed brain parasitic cysts at the cost of local inflammation similar to what is described in human neurocysticercosis. Axonal spheroids and spongy changes as markers of damage were topographically correlated, and not affected by anthelmintic treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13237Subventions
Organisme : NIH HHS
ID : 1R01AI150544-01
Pays : United States
Informations de copyright
© 2024 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.
Références
Donadeu M, Lightowlers MW, Fahrion AS, Kessels J, Abela-Ridder B. Taenia solium: WHO endemicity map update. Wkly Epidemiol Rec. 2016;91:595-599.
Debacq G, Moyano LM, Garcia HH, Boumediene F, Marin B, Ngoungou EB, et al. Systematic review and meta-analysis estimating association of cysticercosis and neurocysticercosis with epilepsy. PLoS Negl Trop Dis. 2017;11:e0005153.
del Brutto OH, Arroyo G, Del Brutto VJ, Zambrano M, García HH. On the relationship between calcified neurocysticercosis and epilepsy in an endemic village: a large-scale, computed tomography-based population study in rural Ecuador. Epilepsia. 2017;58:1955-1961.
Herrick JA, Maharathi B, Kim JS, Abundis GG, Garg A, Gonzales I, et al. Inflammation is a key risk factor for persistent seizures in neurocysticercosis. Ann Clin Transl Neurol. 2018;5:630-639.
Cangalaya C, Zimic M, Marzal M, González AE, Guerra-Giraldez C, Mahanty S, et al. Inflammation caused by praziquantel treatment depends on the location of the Taenia solium cysticercus in porcine neurocysticercosis. PLoS Negl Trop Dis. 2015;9:e0004207.
Sato F, Tanaka H, Hasanovic F, Tsunoda I. Theiler's virus infection: pathophysiology of demyelination and neurodegeneration. Pathophysiology. 2011;18:31-41.
Mahanty S, Orrego MA, Mayta H, Marzal M, Cangalaya C, Paredes A, et al. Post-treatment vascular leakage and inflammatory responses around brain cysts in porcine neurocysticercosis. PLoS Negl Trop Dis. 2015;9:e0003577.
Monk EJM, Abba K, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2021;6:CD000215.
Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Escalante D, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14:687-695.
Bach T, Bae S, D'Cunha R, Winokur P, An G. Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. J Pharm Biomed Anal. 2019;171:111-117.
Bach T, Galbiati S, Kennedy JK, Deye G, Nomicos EYH, Codd EE, et al. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy adults in an open-label phase 1 multiple ascending dose and food effect study. Antimicrob Agents Chemother. 2020;64:e01018-20. https://doi.org/10.1128/AAC.01018-20
An G, Murry DJ, Gajurel K, Bach T, Deye G, Stebounova LV, et al. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy volunteers: a randomized, placebo-controlled first-in-human single-dose escalation study. Antimicrob Agents Chemother. 2019;63:e02255-18. https://doi.org/10.1128/AAC.02255-18
Gonzalez AE, Codd EE, Horton J, Garcia HH, Gilman RH. Oxfendazole: a promising agent for the treatment and control of helminth infections in humans. Expert Rev Anti Infect Ther. 2019;17:51-56.
Verastegui MR, Mejia A, Clark T, Gavidia CM, Mamani J, Ccopa F, et al. Novel rat model for neurocysticercosis using Taenia solium. Am J Pathol. 2015;185:2259-2268.
Mejia Maza A, Carmen-Orozco RP, Carter ES, Dávila-Villacorta DG, Castillo G, Morales JD, et al. Axonal swellings and spheroids: a new insight into the pathology of neurocysticercosis. Brain Pathol. 2019;29:425-436.
Watson GPC. The rat brain in stereotaxic coordinates. 6th ed.Cambridge, MA: Elsevier; 2006.
Carmen-Orozco RP, Dávila-Villacorta DG, Cauna Y, Bernal-Teran EG, Bitterfeld L, Sutherland GL, et al. Blood-brain barrier disruption and angiogenesis in a rat model for neurocysticercosis. J Neurosci Res. 2019;97:137-148.
Restrepo BI, Alvarez JI, Castaño JA, Arias LF, Restrepo M, Trujillo J, et al. Brain granulomas in neurocysticercosis patients are associated with a Th1 and Th2 profile. Infect Immun. 2001;69:4554-4560.
Sikasunge CS, Johansen MV, Phiri IK, Willingham AL 3rd, Leifsson PS. The immune response in Taenia solium neurocysticercosis in pigs is associated with astrogliosis, axonal degeneration and altered blood-brain barrier permeability. Vet Parasitol. 2009;160:242-250.
Maia PD, Hemphill MA, Zehnder B, Zhang C, Parker KK, Kutz JN. Diagnostic tools for evaluating the impact of focal axonal swellings arising in neurodegenerative diseases and/or traumatic brain injury. J Neurosci Methods. 2015;253:233-243.
Gordon N. Infantile neuroaxonal dystrophy (Seitelberger's disease). Dev Med Child Neurol. 2002;44:849-851.
Scheithauer BW, Forno LS, Dorfman LJ, Kane CA. Neuroaxonal dystrophy (Seitelberger's disease) with late onset, protracted course and myoclonic epilepsy. J Neurol Sci. 1978;36:247-258.
Riku Y, Ikeuchi T, Yoshino H, Mimuro M, Mano K, Goto Y, et al. Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site. Acta Neuropathol Commun. 2013;1:12.
Idro R, Marsh K, John CC, Newton CR. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res. 2010;68:267-274.
Medana IM, Day NP, Hien TT, Mai NT, Bethell D, Phu NH, et al. Axonal injury in cerebral malaria. Am J Pathol. 2002;160:655-666.
Sahuquillo J, Vilalta J, Lamarca J, Rubio E, Rodriguez-Pazos M, Salva JA. Diffuse axonal injury after severe head trauma. A clinico-pathological study. Acta Neurochir (Wien). 1989;101:149-158.
Gothwal S, Nayan S. Hallervorden-Spatz syndrome with seizures. Basic Clin Neurosci. 2016;7:165-166.
Born HA. Seizures in Alzheimer's disease. Neuroscience. 2015;286:251-263.
Fang C, Bourdette D, Banker G. Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Mol Neurodegener. 2012;7:29.
Wali G, Liyanage E, Blair NF, Sutharsan R, Park JS, Mackay-Sim A, et al. Oxidative stress-induced axon fragmentation is a consequence of reduced axonal transport in hereditary spastic paraplegia SPAST patient neurons. Front Neurosci. 2020;14:401.
Seo WM, Yoon J, Lee J-H, Lee Y, Lee H, Geum D, et al. Modeling axonal regeneration by changing cytoskeletal dynamics in stem cell-derived motor nerve organoids. Sci Rep. 2022;12:2082.
Tsunoda I, Kuang L-Q, Libbey JE, Fujinami RS. Axonal injury heralds virus-induced demyelination. Am J Pathol. 2003;162:1259-1269.
Edgar JM, McLaughlin M, Yool D, Zhang SC, Fowler JH, Montague P, et al. Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J Cell Biol. 2004;166:121-131.
Rangel R, Torres B, del Bruto O, Sotelo J. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg. 1987;36:387-392.
Srinivas HV, Rao TV, Deshpande DH. Cerebral cysticercosis: clinical and pathological observations with emphasis on the encephalitic type. Clin Neurol Neurosurg. 1980;82:187-197.
Prado RGS, Gardiner CH, Moura MAO, Gonzalez GBE, Duarte MD, Santos TFS, et al. Parasitic encephalitis caused by Stephanurus dentatus in a pig in Brazil. J Vet Diagn Invest. 2021;33:949-951.
Tang TT, Harb JM, Dunne WM Jr, Wells RG, Meyer GA, Chusid MJ, et al. Cerebral toxoplasmosis in an immunocompromised host: a precise and rapid diagnosis by electron microscopy. Am J Clin Pathol. 1986;85:104-110.
Hansen LA, Masliah E, Terry RD, Mirra SS. A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol. 1989;78:194-201.
Seitelberger F. The problem of status Spongiosus. In: Klatzo I, Seitelberger F, editors. Brain edema. Vienna: Springer; 1967. p. 152-169.
Gambetti P, Mellman WJ, Gonatas NK. Familial spongy degeneration of the central nervous system (Van Bogaert-Bertrand disease). Acta Neuropathol. 1969;12:103-115.
Lamfert PW, Schochet SS. Electron microscopic observations on experimental spongy degeneration of the cerebellar White matter. J Neuropathol Exp Neurol. 1968;27:210-220.
Hagen G, Bjerkås I. Spongy degeneration of white matter in the central nervous system of silver foxes (Vulpes vulpes). Vet Pathol. 1990;27:187-193.
Adachi M, Torii J, Schneck L, Volk BW. Electron miscroscopic and enzyme histochemical studies of the cerebellum in spongy degeneration. Acta Neuropathol. 1972;20:22-31.
Anderson TJ, Schneider A, Barrie JA, Klugmann M, McCulloch MC, Kirkham D, et al. Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J Comp Neurol. 1998;394:506-519.
Sasaki S, Warita H, Abe K, Iwata M. Slow component of axonal transport is impaired in the proximal axon of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. 2004;107:452-460.
Yong Y, Hunter-Chang S, Stepanova E, Deppmann C. Axonal spheroids in neurodegeneration. Mol Cell Neurosci. 2021;117:103679.
Ellison D, Love S, Chimelli L, Harding BN, Lowe JS, Vinters HV, et al. Head and spinal injuries. In: Ellison D, Love S, Chimelli L, Harding BN, Lowe JS, Vinters HV, et al., editors. Neuropathology. 3rd ed. Oxford: Mosby; 2013. p. 271-302.
Lino-Junior Rde S, Faleiros AC, Vinaud MC, Oliveira FA, Guimarães JV, Reis MA, et al. Anatomopathological aspects of neurocysticercosis in autopsied patients. Arq Neuropsiquiatr. 2007;65:87-91.
Osorio R, Carrillo-Mezo R, Romo ML, Toledo A, Matus C, González-Hernández I, et al. Factors associated with cysticidal treatment response in extraparenchymal neurocysticercosis. J Clin Pharmacol. 2019;59:548-556.
White AC Jr, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, et al. Diagnosis and treatment of Neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018;66:e49-e75.
Mkupasi EM, Ngowi HA, Sikasunge CS, Leifsson PS, Johansen MV. Efficacy of ivermectin and oxfendazole against Taenia solium cysticercosis and other parasitoses in naturally infected pigs. Acta Trop. 2013;128:48-53.
Sikasunge CS, Johansen MV, Willingham AL 3rd, Leifsson PS, Phiri IK. Taenia solium porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal antigens after treatment with oxfendazole. Vet Parasitol. 2008;158:57-66.
Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2008;79:1050-1055.